BRD4/AKT-IN-1
BRD4/AKT-IN-1 is a BRD4/AKT inhibitor with BRD4 IC50 66.12 nM and AKT1 IC50 143.81 nM. BRD4/AKT-IN-1 blocks BRD4-mediated c-Myc transcriptional regulation, modulates AKT1 signaling, decouples AKT phosphorylation from pro-survival effectors. BRD4/AKT-IN-1 induces G0/G1 cell cycle arrest via downregulated phosphorylated RB, cyclin E1, CDK2. BRD4/AKT-IN-1 elevates LC3B levels to promote autophagy. BRD4/AKT-IN-1 promotes apoptosis in cancer cells. BRD4/AKT-IN-1 can be used for the research of metastatic castration-resistant prostate cancer.
For research use only. We do not sell to patients.
- CAS No.: 3087270-50-3
- Formula: C51H60ClN11O4
- Molecular Weight:926.55
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
BRD4 66.12 nM (IC50) |
Akt1 143.81 nM (IC50) |
CDK2/cyclin E1 |
In Vitro
BRD4/AKT-IN-1 (Compound 21d) (300-1000 nM) potently inhibits purified BRD4 (IC50 = 66.12 nM) and AKT1 (IC50 = 143.81 nM) proteins in a cell-free biochemical HTRF assay[1].
BRD4/AKT-IN-1 (0.01-100 μM; 72 h) potently inhibits the proliferation of 22Rv1 (IC50 = 0.51 μM), VCaP (IC50 = 0.69 μM), and PC3 (IC50 = 4.62 μM) mCRPC cells in a MTT antiproliferation assay[1].
BRD4/AKT-IN-1 (0.5-2 μM; 24 h) induces dose-dependent G0/G1 phase cell cycle arrest in 22Rv1 mCRPC cells by downregulating the expression of p-RB, cyclin E1, and CDK2[1].
BRD4/AKT-IN-1 (0.5-2 μM; 48 h) dose-dependently inhibits the migration of 22Rv1 mCRPC cells in a wound healing assay[1].
BRD4/AKT-IN-1 (0.5-2 μM; 12-14 days) dose-dependently suppresses the long-term clonogenic proliferative capacity of 22Rv1 mCRPC cells[1].
BRD4/AKT-IN-1 (0.5-2 μM; 24 h) dose-dependently suppresses the BRD4/c-Myc pathway and modulates AKT phosphorylation without activating downstream pro-survival signaling in 22Rv1 mCRPC cells after 24 h of treatment[1].
BRD4/AKT-IN-1 (0.5-2 μM; 24 h) dose-dependently induces autophagy in 22Rv1 mCRPC cells after 24 h of treatment, as shown by increased MDC-positive vesicles and elevated LC3B protein levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:22Rv1 mCRPC cells
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:24 h
-
Result:Induced a dose-dependent accumulation of cells in the G0/G1 phase, with 51.9% of untreated cells in G0/G1 increasing to higher proportions with compound treatment.
Downregulated phosphorylated RB (p-RB), cyclin E1, and CDK2 protein levels in a dose-dependent manner.
-
Cell Line:22Rv1 mCRPC cells
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:48 h
-
Result:Demonstrated dose-dependent inhibition of wound closure, with higher concentrations resulting in significantly less migration compared to the control.
-
Cell Line:22Rv1 mCRPC cells
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:12-14 days
-
Result:Significantly reduced colony formation in a dose-dependent manner, with fewer and smaller colonies observed at higher compound concentrations.
-
Cell Line:22Rv1 mCRPC cells
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:24 h
-
Result:Reduced the expression of c-Myc (a BRD4 transcriptional target) in a dose-dependent manner, with efficacy comparable to positive control BRD4 inhibitors.
Induced a dose-dependent increase in p-AKT (Ser473) but did not activate downstream effectors p-PRAS40 and p-S6.
-
Cell Line:22Rv1 mCRPC cells
-
Concentration:0.5 μM; 1 μM; 2 μM
-
Incubation Time:24 h
-
Result:Increased the number of MDC-positive autophagic vesicles in a dose-dependent manner.
Induced a dose-dependent upregulation of LC3B protein levels, confirming autophagy induction.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax |
|---|---|---|---|---|---|
| Mice[1] | 40 mg/kg | i.p. | 6.8 h | 0.25 h | 16967 ng/mL |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (male; subcutaneously injected 22Rv1 cells into the right flank to form a xenograft model)[1]
-
Dosage:40 mg/kg; 80 mg/kg
-
Administration:i.p.; daily; 18 days
-
Result:Achieved a tumor growth inhibition (TGI) rate of 37.7% with no observable body weight loss or treatment-related mortality.
Achieved a TGI rate of 62.0%, which was superior to capivasertib monotherapy, compound 15 monotherapy, and their combination.
Significantly reduced tumor volume and tumor weight compared to controls, with no significant body weight loss or histopathological lesions in major organs (heart, liver, spleen, lung, kidney).
Chemical Information
-
CAS No. 3087270-50-3
-
Molecular Weight 926.55
-
Formula C51H60ClN11O4
-
SMILES
CC1=NOC(C)=C1C2=CC=C3C(C(N(C(N3C)=O)CCCCCC(N4CCN(CC4)CC[C@@H](C5=CC=C(C=C5)Cl)NC(C6(CCN(CC6)C7=C8C=CNC8=NC=N7)N)=O)=O)C9=CC=CC=C9)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)